NGAM Advisors L.P. decreased its stake in shares of Sanofi (NYSE:SNY) by 20.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 383,012 shares of the company’s stock after selling 95,639 shares during the period. NGAM Advisors L.P.’s holdings in Sanofi were worth $18,350,000 as of its most recent filing with the SEC.
A number of other hedge funds have also made changes to their positions in the stock. Guggenheim Capital LLC increased its stake in shares of Sanofi by 1.5% in the fourth quarter. Guggenheim Capital LLC now owns 21,558 shares of the company’s stock worth $872,000 after buying an additional 311 shares in the last quarter. Goodwin Daniel L bought a new position in Sanofi during the second quarter valued at approximately $239,000. Wellington Management Group LLP bought a new position in Sanofi during the first quarter valued at approximately $2,252,000. Cullinan Associates Inc. increased its position in Sanofi by 5.5% in the first quarter. Cullinan Associates Inc. now owns 64,000 shares of the company’s stock valued at $2,896,000 after buying an additional 3,340 shares during the period. Finally, Manning & Napier Advisors LLC increased its position in Sanofi by 8.0% in the first quarter. Manning & Napier Advisors LLC now owns 244,282 shares of the company’s stock valued at $11,052,000 after buying an additional 18,094 shares during the period. Hedge funds and other institutional investors own 9.90% of the company’s stock.
Sanofi (SNY) opened at 48.19 on Friday. The company has a market capitalization of $121.03 billion, a price-to-earnings ratio of 11.43 and a beta of 0.88. Sanofi has a 12-month low of $36.81 and a 12-month high of $50.24. The firm’s 50-day moving average price is $47.84 and its 200 day moving average price is $46.41.
Sanofi (NYSE:SNY) last issued its quarterly earnings data on Monday, July 31st. The company reported $0.74 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.74. The company had revenue of $8.66 billion for the quarter, compared to the consensus estimate of $8.71 billion. Sanofi had a net margin of 25.89% and a return on equity of 25.34%. The company’s revenue for the quarter was down 2.3% on a year-over-year basis. On average, analysts expect that Sanofi will post $3.26 earnings per share for the current year.
SNY has been the subject of a number of recent analyst reports. Zacks Investment Research cut Sanofi from a “buy” rating to a “hold” rating in a report on Tuesday, April 25th. TheStreet raised Sanofi from a “c+” rating to a “b-” rating in a report on Monday, April 24th. Berenberg Bank cut Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, May 11th. BidaskClub cut Sanofi from a “buy” rating to a “hold” rating in a research note on Friday, June 9th. Finally, Argus lifted their target price on Sanofi from $50.00 to $55.00 and gave the company a “buy” rating in a research note on Friday, June 9th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and five have given a buy rating to the stock. Sanofi has a consensus rating of “Hold” and a consensus price target of $54.00.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
What are top analysts saying about Sanofi? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sanofi and related companies.